Dana-Farber sues over anti-lung cancer drug
The Boston Globe reports that Dana Farber Cancer Institute is in the middle of a legal dispute concerning an anticancer molecule discovered by researchers there. The report outlines that Dana-Farber had agreements with two different companies, pharmaceutical giant Novartis and start-up Gatekeeper Pharmaceuticals of Millbrae, CA that appear to be in conflict.
The molecule is targeted at non-small-cell lung cancer with specific gene mutations that make the cancer resist some existing market treatments for the disease. The drug has not yet been through clinical trials.
Disputes over licensing agreements are less well-tested than those concerning patents and other intellectual property. Lawsuits between Gatekeeper and Novartis may be covered by liability insurance depending upon the language of the complaint and the insurance purchased, in particular by start-up, Gatekeeper. Novartis likely self insures this type of risk.